A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient ...

Please provide your email address to receive an email when new articles are posted on . Most patients with sickle cell disease are not using disease-modifying therapies. DMT use increased nearly 10% ...

Patients with stable RRMS who want to discontinue DMT use should be counseled on the need for ongoing follow-up and re-evaluation, and should be advised that continued DMT use is recommended unless ...

Entering the field of psychedelic therapy, whether as a therapist or a client, means learning about an ever-growing, sometimes bewildering array of psychedelic substances. My friends in the field have ...

For sickle cell disease (SCD), hydroxyurea is an established treatment. Despite this, hydroxyurea remains underutilized. New disease-modifying treatments (DMTs), namely, crizanlizumab, L-glutamine, ...

Patients with late-onset MS (LOMS) patients reached disability faster compared with patients with adult-onset MS (AOMS), but these disability milestones were reached later in life, because of the ...